Look Past The Setbacks And Give Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Another Chance

money audit

Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) currently has a daily average trading volume of 1.46M but it saw 1417594 shares traded in last market. With a market cap of 281.69M USD, the company’s current market price of $1.24 came rising about 7.83 while comparing to the previous closing price of $1.15. In past 52 weeks, the stock remained buoying in the range of price level as high as $2.05 and as low as $0.42.

Taking a look at 20-day trading activity of Adaptimmune Therapeutics Plc ADR (ADAP) gives us an average price of $1.1190, while its current price level is -39.51% below from 52-week high level whereas it is 195.24% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.2947 while that of 200 days or SMA-200 reads an average of $0.9117. A closer look into the stock’s movement over the week reveals that its volatility is standing at 10.37% during that period while stretching the period over a month that increases to 10.40%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 55.23 which implies that the stock is in neutral territory.

The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Bryan Garnier which initiated the stock as “Buy” in its note to investors issued on March 24, 2023, recommending a price target of $3.60 for it. Guggenheim upgraded its recommendation for the stock as a “Buy” from “Neutral” on January 03, 2023 while assigning a price target of $5. Mizuho issued its recommendations for the stock as it upgraded the price target for the stock is $9.

Over the week, ADAP’s stock price is moving 8.77% up while it is 20.39% when we observe its performance for the past one month. Year-to-date it is 56.37% up and over the past year, the stock is showing a downside performance of -10.79%.

The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of 0.01 beat the consensus estimate of -0.14 for the same. In next quarter, company is expected to be making quarterly sales of $25.91M as analysts are expecting the sales for current fiscal year at $75.01M and seeing the company making $56.04M in sales next year. Moreover, analysts are in estimates of $10.73M for current-quarter revenue.

Currently, Adaptimmune Therapeutics Plc ADR’s total number of outstanding shares is 227.17M. Company’s return on investment (ROI) stands at -192.17% and return on equity (ROE) at -187.96%. Stock’s beta reads 2.34. Stock has a price to book (P/B) ratio of 7.13 while price to sale or P/S ratio amounts to 4.64. Its return on asset (ROA) is -37.31% on average.